Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The treatment is approved for adolescents aged 12 and older who have a BMI that falls at or above the 95th percentile for their age and sex
despite being taken as a daily pill rather than injection, it contains the same active ingredient and allegedly carries similar risks Mounjaro (tirzepatide): Manufactured by Eli Lilly and approved in May 2022, this medication works as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, offering enhanced blood sugar control and weight loss effects but also allegedly causing severe gastrointestinal injuries similar to semaglutide products Trulicity (dulaglutide): Eli Lillys once-weekly GLP-1 injection approved in 2014 for type 2 diabetes
Understanding compounded tirzepatide testing and quality Quality concerns are legitimate with any compounded medication
Variations in aroma, color, taste and solubility may occur
